Elmind Capital, LP
CIK 0002052213 · NEW YORK, NY · Quarter end: 2026-06-30 · Filed on: 2026-08-14 · Open the SEC source ↗
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.
$398.0M
2026 Q2
Positions
35
Top-10 ConcentrationHow much of the portfolio sits in the 10 largest holdings. High = concentrated bets.
66.6%
Est. Net Flow (Q)
—
2026 Q2
Top Holdings
COGT
COGENT BIOSCIENCES INC
11.4%
SNDX
SYNDAX PHARMACEUTICALS INC
10.2%
CLDX
CELLDEX THERAPEUTICS INC NEW
9.3%
RLAY
RELAY THERAPEUTICS INC
6.9%
PCVX
VAXCYTE INC
6.6%
VERA
VERA THERAPEUTICS INC
4.7%
PHVS
PHARVARIS N V
4.6%
VRDN
VIRIDIAN THERAPEUTICS INC
4.5%
New / Increased
No prior quarter data
Reduced / Exited
No prior quarter data
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.